Inventor
DIEDRICH GUNDO
US17 patents
⚠️ This page may combine multiple inventors who share the name “DIEDRICH GUNDO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MACROGENICS INC
5 patentsUS11459394B2Oct 4, 2022
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
MACROGENICS INC4 citations72
US11242402B2Feb 8, 2022
ADAM9-binding molecules, and methods of use thereof
MACROGENICS INC2 citations71
US11942149B2Mar 26, 2024
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
MACROGENICS INC1 citations62
US12435155B2Oct 7, 2025
CD137 binding molecules and uses thereof
MACROGENICS INC0 citations59
US11795226B2Oct 24, 2023
Bispecific CD16-binding molecules and their use in the treatment of disease
MACROGENICS INC0 citations46
MEDIMMUNE LTD
4 patentsUS9938356B2Apr 10, 2018
Binding molecules specific for CD73 and uses thereof
MEDIMMUNE LTD26 citations92
US10287362B2May 14, 2019
Binding molecules specific for CD73 and uses thereof
MEDIMMUNE LTD10 citations82
US10556968B2Feb 11, 2020
Binding molecules specific for CD73 and uses thereof
MEDIMMUNE LTD2 citations71
US11525012B2Dec 13, 2022
Binding molecules specific for CD73 and uses thereof
MEDIMMUNE LTD0 citations60
LABORATORY CORP AMERICA HOLDINGS
3 patentsUS9766242B2Sep 19, 2017
Methods of determining patient response by measurement of HER-3 and P95
LABORATORY CORP AMERICA HOLDINGS3 citations71
US10775382B2Sep 15, 2020
Methods of determining patient response by measurement of HER-3
LABORATORY CORP AMERICA HOLDINGS0 citations50
US11401344B2Aug 2, 2022
Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
LABORATORY CORP AMERICA HOLDINGS0 citations49